An observational study in Systemic Mastocytoses, sponsored by The First Affiliated Hospital of Soochow University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by The First Affiliated Hospital of Soochow University · Observational
The Registry for Patients With Systemic Mastocytosis in China is a voluntary, observational database that will capture demographic, socioeconomic, and disease information with systemic mastocytosis. No experimental intervention is involved.
Systemic Mastocytosis (SM) is an extremely rare and heterogeneous spectrum of diseases characterized by the buildup of genetically altered mast cells in bone marrow sections and/or other extracutaneous organ(s). SM has not been given enough attention in China at present, and the epidemiological data in China are not clear. To understand the epidemiological characteristics and distribution patterns of SM patients in China. To establish a China-wide database platform for registering SM patients and to develop uniform registration standards and processes; to register SM patients who meet the enrollment criteria nationwide through a multicenter collaborative approach and to collect information on their baseline data, clinical manifestations, laboratory tests, treatment regimens, and follow-up results; to perform quality control and data cleansing on the information collected in the registration database, as well as to perform descriptive and inferential statistical analyses.
55 studies on the registry are indexed under Mastocytosis, Systemic; 14 are open to participants now.
This study's planned enrollment of 150 is close to the median of 150 across 15 observational studies indexed under Mastocytosis, Systemic.
Browse Mastocytosis, Systemic studies →The First Affiliated Hospital of Soochow University is the lead sponsor of 258 studies on the registry; 149 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a diagnosis of systemic mastocytosis according to World Health Organization (WHO) classification, including subtypes of SM, who is willing and able to provide written online informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Any patient with a diagnosis of systemic mastocytosis according to World Health Organization (WHO) classification, including subtypes of SM, who is willing and able to provide written online informed consent.
Exclusion Criteria:
None
The morbidity rate over 2 years ofSystemic Mastocytosis and its subtypes (cases per 1,000 individuals per year)
Evaluation of the morbidity rate over 2 years of Systemic Mastocytosis and its subtypes including Bone marrow mastocytosis (BMM), Indolent SM, Smoldering SM, Aggressive SM, SM with an associated hematologic neoplasm and Mast cell leukemia. (cases per 1,000 individuals per year)
Time frame: at 2 year
Demographic characteristics of Systemic Mastocytosis
1. The median age of Systemic Mastocytosis patients (year-old); 2. The sex distribution of Systemic Mastocytosis patients (M/F ratio\[0-1\]); 3. The ECOG score of Systemic Mastocytosis patients (score\[0-5\]); 4. The geographic distribution of Systemic Mastocytosis patients (% per province\[0-100\]);
Time frame: at 2 year
Hematological characteristics of Systemic Mastocytosis
1. The neutrophils, eosinophils, basophils, and mast cells in WBC classification (%); 2. The proliferative degree in sections of BM (%); 3. The ratio of mast cells in BM smear and FCM (%); 4. The ratio of expression of CD25, CD2, and CD30 in FCM (%); 5. The serum tryptase level(%).
Time frame: at 2 year
Nonhematological characteristics of Systemic Mastocytosis
1. The incidence of extramedullary organ infiltration including skin, bone and other organs (%); 2. The incidence of enlarged liver (%); 3. The incidence of enlarged spleen (%); 4. The incidence of enlarged lymphnodes (%); 5. The incidence of hypoproteinemia and loss weight (%).
Time frame: at 2 year
Responses to therapy of Systemic Mastocytosis
1. The rate of eligible complete remission (CR) patients(%); 2. The rate of eligible partial remission (PR) patients(%); 3. The rate of eligible clincal improvement (CI) patients(%); 4. The rate of eligible stable disease (SD) patients(%); 5. The rate of eligible progressive disease (PD) patients(%); 6. The rate of eligible loss of reponse (LOR) patients(%).
Time frame: at 2 year
Survival Distribution of Systemic Mastocytosis
1. Overall survival (months): Measured the time from enrollment to the date of the last follow-up or death; 2. Event-free survival (months): Measured the time from the date of attaining CR1 until the first relapse, death, or the final follow-up day.
Time frame: at 2 year
This study is status unknown, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Soochow University →